• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

现有的原发性肝癌分期系统是否适用于肝细胞癌-肝内胆管癌?

Do the existing staging systems for primary liver cancer apply to combined hepatocellular carcinoma-intrahepatic cholangiocarcinoma?

机构信息

Department of Liver Surgery, Liver Cancer Institute, Zhongshan Hospital, and Key Laboratory of Carcinogenesis and Cancer Invasion (Ministry of Education), Fudan University, Shanghai 200032, China.

Department of Pathology, Zhongshan Hospital, Fudan University, Shanghai 200032, China.

出版信息

Hepatobiliary Pancreat Dis Int. 2021 Feb;20(1):13-20. doi: 10.1016/j.hbpd.2020.10.002. Epub 2020 Oct 27.

DOI:10.1016/j.hbpd.2020.10.002
PMID:33160852
Abstract

BACKGROUND

The incidence of combined hepatocellular carcinoma-intrahepatic cholangiocarcinoma (cHCC-ICC) is relatively low, and the knowledge about the prognosis of cHCC-ICC remains obscure. In the study, we aimed to screen existing primary liver cancer staging systems and shed light on the prognosis and risk factors for cHCC-ICC.

METHODS

We retrospectively reviewed 206 cHCC-ICC patients who received curative surgical resection from April 1999 to March 2017. The correlation of survival measures with the histological types or with tumor staging systems was determined and predictive values of tumor staging systems with cHCC-ICC prognosis were compared.

RESULTS

The histological type was not associated with overall survival (OS) (P = 0.338) or disease-free survival (DFS) (P = 0.843) of patients after curative surgical resection. BCLC, TNM for HCC, and TNM for ICC stages correlated with both OS and DFS in cHCC-ICC (all P < 0.05). The predictive values of TNM for HCC and TNM for ICC stages were similar in terms of predicting postoperative OS (P = 0.798) and DFS (P = 0.191) in cHCC-ICC. TNM for HCC was superior to BCLC for predicting postoperative OS (P = 0.022) in cHCC-ICC.

CONCLUSION

The TNM for HCC staging system should be prioritized for clinical applications in predicting cHCC-ICC prognosis.

摘要

背景

肝细胞癌-胆管细胞癌(cHCC-ICC)的发病率相对较低,其预后知识仍不清楚。本研究旨在筛选现有的原发性肝癌分期系统,并探讨 cHCC-ICC 的预后及危险因素。

方法

我们回顾性分析了 1999 年 4 月至 2017 年 3 月接受根治性手术切除的 206 例 cHCC-ICC 患者。确定生存措施与组织学类型或肿瘤分期系统的相关性,并比较肿瘤分期系统对 cHCC-ICC 预后的预测价值。

结果

根治性手术后,组织学类型与患者的总生存(OS)(P=0.338)或无病生存(DFS)(P=0.843)无关。BCLC、HCC 的 TNM 分期和 ICC 的 TNM 分期均与 cHCC-ICC 的 OS 和 DFS 相关(均 P<0.05)。在预测 cHCC-ICC 的术后 OS(P=0.798)和 DFS(P=0.191)方面,HCC 的 TNM 分期和 ICC 的 TNM 分期的预测价值相似。在 cHCC-ICC 中,TNM 分期对 HCC 优于 BCLC 预测术后 OS(P=0.022)。

结论

在预测 cHCC-ICC 的预后方面,HCC 的 TNM 分期系统应优先用于临床应用。

相似文献

1
Do the existing staging systems for primary liver cancer apply to combined hepatocellular carcinoma-intrahepatic cholangiocarcinoma?现有的原发性肝癌分期系统是否适用于肝细胞癌-肝内胆管癌?
Hepatobiliary Pancreat Dis Int. 2021 Feb;20(1):13-20. doi: 10.1016/j.hbpd.2020.10.002. Epub 2020 Oct 27.
2
The Predictive Value of Staging Systems and Inflammation Scores for Patients with Combined Hepatocellular Cholangiocarcinoma After Surgical Resection: a Retrospective Study.联合肝细胞胆管细胞癌患者手术后分期系统和炎症评分的预测价值:一项回顾性研究。
J Gastrointest Surg. 2018 Jul;22(7):1239-1250. doi: 10.1007/s11605-018-3756-3. Epub 2018 Apr 17.
3
The clinical characteristics and prognostic factors of combined Hepatocellular Carcinoma and Cholangiocarcinoma, Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma after Surgical Resection: A propensity score matching analysis.肝细胞癌合并胆管细胞癌、肝细胞癌和肝内胆管细胞癌术后的临床特征和预后因素:倾向评分匹配分析。
Int J Med Sci. 2021 Jan 1;18(1):187-198. doi: 10.7150/ijms.50883. eCollection 2021.
4
[Comparison of the Predictive Values of Eight Staging Systems for Primary Liver Cancer in Prognosis of Combined Hepatocellular-cholangiocellular Carcinoma Patients after Surgery].[八种分期系统对原发性肝癌合并肝细胞-胆管细胞癌患者术后预后的预测价值比较]
Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2016 Apr;38(2):175-81. doi: 10.3881/j.issn.1000-503X.2016.02.009.
5
Combined hepatocellular carcinoma and cholangiocarcinoma: clinical features, treatment modalities, and prognosis.肝细胞癌合并胆管细胞癌:临床特征、治疗方式和预后。
Ann Surg Oncol. 2012 Sep;19(9):2869-76. doi: 10.1245/s10434-012-2328-0. Epub 2012 Mar 27.
6
Clinicopathological features and prognosis of combined hepatocellular carcinoma and cholangiocarcinoma after surgery.肝细胞癌合并胆管癌术后的临床病理特征及预后
Hepatobiliary Pancreat Dis Int. 2014 Dec;13(6):594-601. doi: 10.1016/s1499-3872(14)60275-7.
7
Radiological features and outcomes of combined hepatocellular-cholangiocarcinoma in patients undergoing surgical resection.手术切除治疗肝细胞-胆管细胞混合癌患者的放射学特征和结局。
J Formos Med Assoc. 2020 Jan;119(1 Pt 1):125-133. doi: 10.1016/j.jfma.2019.02.012. Epub 2019 Mar 12.
8
Combined hepatocellular-cholangiocarcinoma: a population-level analysis of an uncommon primary liver tumor.肝细胞-胆管细胞癌:一种罕见原发性肝癌的人群水平分析
Liver Transpl. 2014 Aug;20(8):952-9. doi: 10.1002/lt.23897. Epub 2014 Jul 3.
9
Characteristics of combined hepatocelluar-cholangiocarcinoma and comparison with intrahepatic cholangiocarcinoma.肝细胞-胆管癌合并症的特征及与肝内胆管癌的比较。
Eur J Surg Oncol. 2014 Aug;40(8):976-81. doi: 10.1016/j.ejso.2014.04.016. Epub 2014 May 23.
10
The significance of the predominant component in combined hepatocellular-cholangiocarcinoma: MRI manifestation and prognostic value.混合细胞型肝癌的主要成分的意义:MRI 表现与预后价值。
Radiol Med. 2023 Sep;128(9):1047-1060. doi: 10.1007/s11547-023-01682-x. Epub 2023 Jul 20.

引用本文的文献

1
CLDN4 palmitoylation promotes hepatic-to-biliary lineage transition and lenvatinib resistance in hepatocellular carcinoma.紧密连接蛋白4(CLDN4)的棕榈酰化促进肝细胞癌中肝向胆管谱系转变及乐伐替尼耐药。
Cell Rep Med. 2025 Jul 15;6(7):102208. doi: 10.1016/j.xcrm.2025.102208. Epub 2025 Jun 30.
2
A blood test-based nomogram to predict the progression-free survival of patients with intrahepatic cholangiocarcinoma after surgical resection.一种基于血液检测的列线图,用于预测肝内胆管癌患者手术切除后的无进展生存期。
Front Oncol. 2025 Jun 9;15:1507602. doi: 10.3389/fonc.2025.1507602. eCollection 2025.
3
Update on the Diagnosis and Treatment of Combined Hepatocellular Cholangiocarcinoma.
肝细胞胆管癌联合诊断与治疗的最新进展
J Clin Transl Hepatol. 2024 Feb 28;12(2):210-217. doi: 10.14218/JCTH.2023.00189. Epub 2023 Nov 15.
4
Efficacy and safety of hepatic artery infusion chemotherapy with mFOLFOX in primary liver cancer patients with hyperbilirubinemia and ineffective drainage: a retrospective cohort study.mFOLFOX肝动脉灌注化疗在高胆红素血症且引流无效的原发性肝癌患者中的疗效与安全性:一项回顾性队列研究
Ann Transl Med. 2022 Apr;10(7):411. doi: 10.21037/atm-22-978.
5
Sarcopenia predicts an adverse prognosis in patients with combined hepatocellular carcinoma and cholangiocarcinoma after surgery.肌肉减少症预示着接受手术治疗的肝细胞癌合并胆管细胞癌患者预后不良。
Cancer Med. 2022 Jan;11(2):317-331. doi: 10.1002/cam4.4448. Epub 2021 Dec 5.
6
Prediction of Survival and Analysis of Prognostic Factors for Patients With Combined Hepatocellular Carcinoma and Cholangiocarcinoma: A Population-Based Study.肝细胞癌合并胆管癌患者生存预测及预后因素分析:一项基于人群的研究
Front Oncol. 2021 Jul 16;11:686972. doi: 10.3389/fonc.2021.686972. eCollection 2021.
7
Current challenges to underpinning the genetic basis for cholangiocarcinoma.当前支持胆管癌遗传基础的挑战。
Expert Rev Gastroenterol Hepatol. 2021 May;15(5):511-526. doi: 10.1080/17474124.2021.1915128. Epub 2021 Apr 23.